Thermo Fisher Scientific has reported that its revenues increased 1% to a record $2.65 billion in the fourth quarter of 2008, compared with $2.62 billion the previous year. For the whole year revenues grew 8% to a record $10.5 billion compared with $9.75 billion previously.
Thermo Fisher Scientific has reported that its revenues increased 1% to a record $2.65 billion in the fourth quarter of 2008, compared with $2.62 billion the previous year. For the whole year revenues grew 8% to a record $10.5 billion compared with $9.75 billion previously.
“We are pleased to report very solid financial results for both the fourth quarter and the full year in spite of the economic headwinds that continue to put pressure on capital spending in some of our end markets,” said Marijn E. Dekkers, president and chief executive officer of the company. “Our performance is largely the result of our favorable product mix, with two-thirds of our revenues coming from recurring sales of consumables and services that tend to hold up better in an uncertain environment.”
Dekkers also predicted how the company would perform in the coming year; “The economic climate will likely continue to restrain capital budgets, especially through the first half of the year. Based on that assumption, and a negative impact of approximately 4% from foreign exchange, we expect to achieve 2009 revenues of $10.0 to $10.3 billion, or a 2 to 5% decline compared with 2008.”
Visit the company’s website, www.thermofisher.com to access more detailed financial reports.
Evaluating Antimicrobial Potential of Articaine Derivatives in Oral Infections with CMC
May 20th 2025Cell membrane chromatography (CMC) technology was used by researchers in screening efficacy and antibacterial ability of articaine (AT) derivatives in the pre-emptive treatment of oral infections.
Hydrophilic Interaction Chromatography (HILIC) and Direct Online Disruption of Lipid Nanoparticles
May 19th 2025Two proof-of-concept hydrophilic interaction chromatography HILIC) methods were developed in a joint study conducted by the University of Geneva (Switzerland), Sanofi, and the Waters Corporation—one for disrupting LNPs and retaining the mRNA, and another for detecting only unencapsulated mRNA to assess encapsulation efficiency. LCGC International spoke to Jonathan Maurer, first author of the paper that resulted from this study, about the methods and the efforts that led up to their development.
This article discusses how integrating seven prioritization strategies can enhance compound identification, support environmental risk assessment, and accelerate decision-making.